Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Coinbase Global, Inc. (COIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Coinbase Global, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.01 (market cap $29.60B), while Coinbase Global, Inc. trades at $149.58 (market cap $39.20B). The key difference: Coinbase Global, Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| ALNY | COIN | |
|---|---|---|
Market Cap | $29.60B | $39.20B |
Sector | Health | Technology |
52-Week High | $491.22 | $387.27 |
52-Week Low | $205.48 | $141.09 |
Enterprise Value | $27.56B | $36.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
COIN trades at $150.35, up 1.12% with bearish technical signals but strong analyst support (55% buy ratings). The company reported mixed Q2 2026 results with revenue and EPS misses, though it achieved a record 10.3% global trading volume share. Fundamentals show revenue growth from $3.1B in 2023 to $7.2B in 2025, but profitability remains volatile with recent quarterly losses.
The stock faces near-term pressure from earnings misses and crypto market volatility, but long-term potential exists through business diversification beyond retail trading. Key risks include competitive threats and regulatory uncertainty, while the $207.20 consensus price target suggests 38% upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Coinbase Global, Inc.
Coinbase Global, Inc. is a regulated cryptocurrency company that provides customers around the world with a platform for buying, selling, transferring, and storing digital assets. The Company offers a variety of products and services that enable individuals, businesses, and developers to participate in the cryptoeconomy.
Read more on COIN →
